Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
BRAF
Namespace
HGNC
Namespace Version
20150611
Namespace URL
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-human-genes/hgnc-human-genes-20150601.belns

Appears in Networks 17

BEL Framework Large Corpus Document v20170611

Approximately 61,000 statements. This is a modified version of the original to use namespace files hosted on Artifactory

Senescence-2.0-Hs v2.0

The Mechanisms of Cellular Senescence network depicts the causal mechanisms that are involved in induction of senescence in non-transformed cells in response to a variety of external stimuli (including replicative senescence, stress-induced senescence, and oncogene-induced senescence). The network includes components that participate in intercellular signaling such as growth factors, chemokines, cytokines and proteases, which ultimately lead to manifestation of the senescence-associated secretory phenotype (SASP). \nReviewed during Jamboree2015

Senescence-2.0-Mm v2.0

The Mechanisms of Cellular Senescence network depicts the causal mechanisms that are involved in induction of senescence in non-transformed cells in response to a variety of external stimuli (including replicative senescence, stress-induced senescence, and oncogene-induced senescence). The network includes components that participate in intercellular signaling such as growth factors, chemokines, cytokines and proteases, which ultimately lead to manifestation of the senescence-associated secretory phenotype (SASP). \nReviewed during Jamboree2015

Senescence-2.0-Rn v2.0

The Mechanisms of Cellular Senescence network depicts the causal mechanisms that are involved in induction of senescence in non-transformed cells in response to a variety of external stimuli (including replicative senescence, stress-induced senescence, and oncogene-induced senescence). The network includes components that participate in intercellular signaling such as growth factors, chemokines, cytokines and proteases, which ultimately lead to manifestation of the senescence-associated secretory phenotype (SASP). \nReviewed during Jamboree2015

Colorectal Cancer Knowledge Assembly - Drugs Pathways and General Biology v1.1.0

Colorectal Cancer Knowledge Assembly with drug associations and Pathways + general CRC biology

colorectal cancer Knowledge Assembly - Drugs v1.0.1

colorectal cancer Knowledge Assembly with drug associations.

Colorectal Cancer Model v1.0.0

Colorectal Cancer Model built for i:DSem-BMBF project.

colorectal cancer Drugs resistance v1.0.1.0

colorectal cancer Knowledge Assembly with drug associations.

CRC_combined v1.1

BEL Document

Colorectal Cancer Model v2.0.0

Colorectal Cancer Model

Colorectal Cancer Model v0.0.0

Colorectal Cancer Model

Colorectal Cancer Model v2.0.3

Colorectal Cancer Model

Colorectal Cancer Model v2.0.4

Colorectal Cancer Model, uploaded by reagon

Colorectal Cancer Model v2.0.5

Colorectal Cancer Model, uploaded by reagon

Colorectal Cancer Model v2.0.6

Colorectal Cancer Model, uploaded by reagon

In-Edges 50

path(MESHD:"Colorectal Neoplasms") association p(HGNC:BRAF, var(p.Val600Glu))

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

path(MESHD:"Carcinoma, Medullary") positiveCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

path(MESHD:Neoplasms) association p(HGNC:BRAF, var(p.Val600Glu))

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

path(DO:"neuroendocrine carcinoma") association p(HGNC:BRAF, var(p.Val600Glu))

BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D). PubMed:23114745

path(MESHD:"Adenoma, Villous") negativeCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

bp(GOBP:"immune response") association p(HGNC:BRAF, var(p.Val600Glu))

These findings suggest that future trials combining specific BRAF(V600E) inhibition with immunotherapy should not impair immune response. PubMed:22355009

Annotations
MeSH
Peroxisomes
Experimental Factor Ontology (EFO)
COLO205
MeSH
Melanoma
Evidence and Conclusion Ontology
dominant_negative mutant
MeSH
Blood Platelets
MeSH
Endothelium, Vascular
NCBI Taxonomy Names
Homo sapiens
NCBI Taxonomy Ids
10117

a(CHEBI:dabrafenib) decreases p(HGNC:BRAF, var(p.Val600Glu))

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. PubMed:22355009

Annotations
MeSH
Peroxisomes
Experimental Factor Ontology (EFO)
COLO205
MeSH
Colonic Neoplasms
Evidence and Conclusion Ontology
dominant_negative mutant
MeSH
Blood Platelets
MeSH
Endothelium, Vascular
NCBI Taxonomy Names
Homo sapiens
NCBI Taxonomy Ids
10117

a(CHEBI:dabrafenib) decreases p(HGNC:BRAF, var(p.Val600Glu))

Although pharmacologic inhibition of BRAF(V600E) in melanoma patients, which is linked to immune suppression, results in an initial response rate, these responses are typically of limited duration. PubMed:22355009

Annotations
MeSH
Peroxisomes
Experimental Factor Ontology (EFO)
COLO205
MeSH
Melanoma
Evidence and Conclusion Ontology
dominant_negative mutant
MeSH
Blood Platelets
MeSH
Endothelium, Vascular
NCBI Taxonomy Names
Homo sapiens
NCBI Taxonomy Ids
10117

path(MESHD:"Colorectal Neoplasms") association p(HGNC:BRAF, var(p.Val600Glu))

The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high frequency in melanoma and certain subtypes of colorectal cancer. PubMed:23406774

Annotations
Experimental Factor Ontology (EFO)
SW620 cell
MeSH
Colonic Neoplasms
Evidence and Conclusion Ontology
RNAi
MeSH
Colon
NCBI Taxonomy Names
Homo sapiens

bp(GOBP:"Wnt signaling pathway") association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
NCBI Taxonomy Ids
9606
Experimental Factor Ontology (EFO)
SW480
Disease Ontology (DO)
colorectal cancer
MeSH
Neoplasms

bp(GOBP:"phosphatidylinositol 3-kinase signaling") association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
NCBI Taxonomy Ids
9606
Experimental Factor Ontology (EFO)
SW480
Disease Ontology (DO)
colorectal cancer
MeSH
Neoplasms

p(HGNC:SHH) association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
NCBI Taxonomy Ids
9606
Experimental Factor Ontology (EFO)
SW480
Disease Ontology (DO)
colorectal cancer
MeSH
Neoplasms

bp(GOBP:"Wnt signaling pathway") association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
MeSH
Microtubules
Experimental Factor Ontology (EFO)
SW480
MeSH
Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
9606

bp(GOBP:"phosphatidylinositol 3-kinase signaling") association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
MeSH
Microtubules
Experimental Factor Ontology (EFO)
SW480
MeSH
Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
9606

p(HGNC:SHH) association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
MeSH
Microtubules
Experimental Factor Ontology (EFO)
SW480
MeSH
Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
9606

path(MESHD:"Carcinoma, Medullary") positiveCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

path(MESHD:"Adenoma, Villous") negativeCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

path(MESHD:Neoplasms) association p(HGNC:BRAF, var(p.Val600Glu))

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

Annotations
NCBI Taxonomy Ids
9606
Uberon
colon

path(MESHD:"Colorectal Neoplasms") association p(HGNC:BRAF, var(p.Val600Glu))

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

path(DO:"neuroendocrine carcinoma") association p(HGNC:BRAF, var(p.Val600Glu))

BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D). PubMed:23114745

bp(GOBP:"Wnt signaling pathway") association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

bp(GOBP:"phosphatidylinositol 3-kinase signaling") association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

p(HGNC:SHH) association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

path(MESHD:"Adenoma, Villous") negativeCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

Appears in Networks:
Annotations
MeSH
Cytoplasm
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Uberon
colon

path(MESHD:"Carcinoma, Medullary") positiveCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

Appears in Networks:
Annotations
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
NCBI Taxonomy Names
Mus musculus

path(MESHD:Neoplasms) association p(HGNC:BRAF, var(p.Val600Glu))

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

Appears in Networks:
Annotations
MeSH
Cytoplasm
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Uberon
colon
NCBI Taxonomy Ids
9606

path(MESHD:"Colorectal Neoplasms") association p(HGNC:BRAF, var(p.Val600Glu))

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

Appears in Networks:
Annotations
MeSH
Cytoplasm
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
NCBI Taxonomy Names
Mus musculus

path(DO:"neuroendocrine carcinoma") association p(HGNC:BRAF, var(p.Val600Glu))

BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D). PubMed:23114745

Appears in Networks:
Annotations
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
NCBI Taxonomy Names
Mus musculus

bp(GOBP:"immune response") association p(HGNC:BRAF, var(p.Val600Glu))

These findings suggest that future trials combining specific BRAF(V600E) inhibition with immunotherapy should not impair immune response. PubMed:22355009

Annotations
Experimental Factor Ontology (EFO)
SW620 cell
Experimental Factor Ontology (EFO)
WiDr cell
Experimental Factor Ontology (EFO)
HCT116
Experimental Factor Ontology (EFO)
HCT15
MeSH
Peroxisomes
MeSH
Melanoma
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Macrophages
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

path(MESHD:"Adenoma, Villous") negativeCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

Annotations
Experimental Factor Ontology (EFO)
DLD-1 cell
MeSH
Cytoplasm
MeSH
Colorectal Neoplasms
MeSH
Colon
Uberon
colon
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

bp(GOBP:"phosphatidylinositol 3-kinase signaling") association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
Experimental Factor Ontology (EFO)
SW480
MeSH
Intracellular Space
MeSH
Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

path(MESHD:"Colorectal Neoplasms") association p(HGNC:BRAF, var(p.Val600Glu))

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

path(MESHD:"Colorectal Neoplasms") association p(HGNC:BRAF, var(p.Val600Glu))

The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high frequency in melanoma and certain subtypes of colorectal cancer. PubMed:23406774

Annotations
Experimental Factor Ontology (EFO)
SW1116 cell
MeSH
Microtubules
MeSH
Neoplasms
Evidence and Conclusion Ontology
cell viability assay
MeSH
Serum
MeSH
Plasma
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

path(DO:"neuroendocrine carcinoma") association p(HGNC:BRAF, var(p.Val600Glu))

BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D). PubMed:23114745

path(MESHD:"Carcinoma, Medullary") positiveCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

a(CHEBI:dabrafenib) decreases p(HGNC:BRAF, var(p.Val600Glu))

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. PubMed:22355009

Annotations
Experimental Factor Ontology (EFO)
SW620 cell
Experimental Factor Ontology (EFO)
WiDr cell
Experimental Factor Ontology (EFO)
HCT116
Experimental Factor Ontology (EFO)
HCT15
MeSH
Peroxisomes
MeSH
Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Macrophages
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

a(CHEBI:dabrafenib) decreases p(HGNC:BRAF, var(p.Val600Glu))

Although pharmacologic inhibition of BRAF(V600E) in melanoma patients, which is linked to immune suppression, results in an initial response rate, these responses are typically of limited duration. PubMed:22355009

Annotations
Experimental Factor Ontology (EFO)
SW620 cell
Experimental Factor Ontology (EFO)
WiDr cell
Experimental Factor Ontology (EFO)
HCT116
Experimental Factor Ontology (EFO)
HCT15
MeSH
Peroxisomes
MeSH
Melanoma
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Macrophages
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

bp(GOBP:"Wnt signaling pathway") association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
Experimental Factor Ontology (EFO)
SW480
MeSH
Intracellular Space
MeSH
Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

p(HGNC:SHH) association p(HGNC:BRAF, var(p.Val600Glu))

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
Experimental Factor Ontology (EFO)
SW480
MeSH
Intracellular Space
MeSH
Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

path(MESHD:Neoplasms) association p(HGNC:BRAF, var(p.Val600Glu))

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

Annotations
Experimental Factor Ontology (EFO)
DLD-1 cell
MeSH
Cytoplasm
MeSH
Colorectal Neoplasms
MeSH
Colon
Uberon
colon
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

bp(GOBP:"immune response") association p(HGNC:BRAF, var(p.Val600Glu))

These findings suggest that future trials combining specific BRAF(V600E) inhibition with immunotherapy should not impair immune response. PubMed:22355009

path(MESHD:"Adenoma, Villous") negativeCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

path(MESHD:"Colorectal Neoplasms") association p(HGNC:BRAF, var(p.Val600Glu))

The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high frequency in melanoma and certain subtypes of colorectal cancer. PubMed:23406774

path(MESHD:"Carcinoma, Medullary") positiveCorrelation p(HGNC:BRAF, var(p.Val600Glu))

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

a(CHEBI:dabrafenib) decreases p(HGNC:BRAF, var(p.Val600Glu))

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. PubMed:22355009

a(CHEBI:dabrafenib) decreases p(HGNC:BRAF, var(p.Val600Glu))

Although pharmacologic inhibition of BRAF(V600E) in melanoma patients, which is linked to immune suppression, results in an initial response rate, these responses are typically of limited duration. PubMed:22355009

path(MESHD:Neoplasms) association p(HGNC:BRAF, var(p.Val600Glu))

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

path(MESHD:"Colorectal Neoplasms") association p(HGNC:BRAF, var(p.Val600Glu))

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

Out-Edges 134

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:12068308

Annotations
Experimental Factor Ontology (EFO)
Caco-2 cell
NCBI Taxonomy Ids
9606
Uberon
brain
Cell Ontology (CL)
smooth muscle cell
MeSH
Cell Nucleus
Disease Ontology (DO)
lymphoma

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:12670889

Annotations
Experimental Factor Ontology (EFO)
HCT 116 cell
NCBI Taxonomy Ids
9606
Uberon
prostate gland
Cell Ontology (CL)
muscle cell
MeSH
Cytoplasm
Disease Ontology (DO)
skin cancer

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:12778069

Annotations
Experimental Factor Ontology (EFO)
NIH-3T3 cell
NCBI Taxonomy Ids
9606
Uberon
smooth muscle tissue
Cell Ontology (CL)
type B pancreatic cell
MeSH
Cell Nucleus
Disease Ontology (DO)
multiple myeloma

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:12794760

Annotations
Experimental Factor Ontology (EFO)
HeLa cell
NCBI Taxonomy Ids
9606
Uberon
endothelium
Cell Ontology (CL)
B cell
MeSH
Cell Membrane
Disease Ontology (DO)
breast cancer

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:12819038

Annotations
Experimental Factor Ontology (EFO)
HaCaT
NCBI Taxonomy Ids
9606
Uberon
endothelium
Cell Ontology (CL)
cardiac muscle cell
MeSH
Cell Nucleus
Disease Ontology (DO)
adenocarcinoma

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:14602780

Annotations
Experimental Factor Ontology (EFO)
MIA PaCa-2 cell
NCBI Taxonomy Ids
9606
Uberon
intestine
Cell Ontology (CL)
astrocyte
MeSH
Cell Nucleus
Disease Ontology (DO)
neuroblastoma

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:14668801

Annotations
Experimental Factor Ontology (EFO)
HT-1080 cell
NCBI Taxonomy Ids
9606
Uberon
thyroid gland
Cell Ontology (CL)
neutrophil
MeSH
Cell Membrane
Disease Ontology (DO)
brain glioma

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:14734469

Annotations
Experimental Factor Ontology (EFO)
MEF cell line
NCBI Taxonomy Ids
9606
Uberon
aorta
Cell Ontology (CL)
macrophage
MeSH
Cell Nucleus
Disease Ontology (DO)
atherosclerosis

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:14961576

Annotations
Experimental Factor Ontology (EFO)
MKN-45 cell
NCBI Taxonomy Ids
9606
Uberon
endothelium
Cell Ontology (CL)
endothelial cell
MeSH
Cytoplasm
Disease Ontology (DO)
atherosclerosis

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:15009714

Annotations
Experimental Factor Ontology (EFO)
293T/17 cell
NCBI Taxonomy Ids
9606
Uberon
cardiovascular system
Cell Ontology (CL)
macrophage
MeSH
Cell Nucleus
Disease Ontology (DO)
lung cancer

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:15191558

Annotations
Experimental Factor Ontology (EFO)
MCF7 cell
NCBI Taxonomy Ids
9606
Uberon
thyroid gland
Cell Ontology (CL)
monocyte
MeSH
Cell Nucleus
Disease Ontology (DO)
lung cancer

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:15294323

Annotations
Experimental Factor Ontology (EFO)
L6 cell
NCBI Taxonomy Ids
9606
Uberon
skeletal muscle tissue
Cell Ontology (CL)
skeletal muscle satellite cell
MeSH
Cytoplasm
Disease Ontology (DO)
gastric adenocarcinoma

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:15467732

Annotations
Experimental Factor Ontology (EFO)
LNCAP cell
NCBI Taxonomy Ids
9606
Uberon
prostate gland
Cell Ontology (CL)
endothelial cell
MeSH
Extracellular Space
Disease Ontology (DO)
melanoma
MeSH
Hypercholesterolemia

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:15588860

Annotations
Experimental Factor Ontology (EFO)
MCF7 cell
NCBI Taxonomy Ids
9606
Uberon
endothelium
Cell Ontology (CL)
lymphocyte
MeSH
Cytoplasm
Disease Ontology (DO)
colon cancer
MeSH
Head and Neck Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:15782137

Annotations
Experimental Factor Ontology (EFO)
THP-1 cell
NCBI Taxonomy Ids
9606
Uberon
skeletal muscle tissue
Cell Ontology (CL)
T cell
MeSH
Cell Membrane
Disease Ontology (DO)
breast cancer
MeSH
Sputum
MeSH
Head and Neck Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:16001072

Annotations
Experimental Factor Ontology (EFO)
NIH-3T3 cell
NCBI Taxonomy Ids
9606
Uberon
lens of camera-type eye
Cell Ontology (CL)
monocyte
MeSH
Cell Nucleus
Disease Ontology (DO)
colon cancer
MeSH
Sputum
MeSH
Head and Neck Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) directlyIncreases act(p(HGNC:BRAF), ma(kin))

From mutations file PubMed:16170021

Annotations
Experimental Factor Ontology (EFO)
HeLa cell
NCBI Taxonomy Ids
9606
Uberon
lung
Cell Ontology (CL)
macrophage
MeSH
Extracellular Matrix
Disease Ontology (DO)
breast cancer
MeSH
Sputum
MeSH
Head and Neck Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) increases path(SDIS:"Oncogene induced senescence")

Following expression of BRAFV600E in melanocytes, the majority of cells became senescent (Figure 1D and data not shown), consistent with previous studies (Michaloglou et al., 2005) PubMed:18267069

Annotations
Experimental Factor Ontology (EFO)
SK-N-MC cell
NCBI Taxonomy Ids
9606
Uberon
cardiovascular system
Cell Ontology (CL)
melanocyte
MeSH
Cell Nucleus
Disease Ontology (DO)
breast cancer
MeSH
Sputum
MeSH
Head and Neck Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) increases path(SDIS:"Oncogene induced senescence")

In the present study, we found that when RSK4 is inhibited in vitro using short hairpin RNA technology, cells can bypass stress-induced senescence and oncogene-induced senescence: normal human fibroblasts grew following oxidative stress, induction of DNA damage and KRAS(V12) or BRAF(E600) overexpression. PubMed:21239520

Annotations
Experimental Factor Ontology (EFO)
IMR-90 cell
NCBI Taxonomy Ids
9606
Uberon
respiratory airway
Cell Ontology (CL)
fibroblast
MeSH
Cell Membrane
Disease Ontology (DO)
glioblastoma multiforme
MeSH
Sputum
MeSH
Head and Neck Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) increases p(HGNC:IGFBP7)

Here we perform genome-wide RNA-interference screening to identify 17 genes required for an activated BRAF oncogene (BRAFV600E) to block proliferation of human primary fibroblasts and melanocytes. Surprisingly, we find a secreted protein, IGFBP7, has a central role in BRAFV600E-mediated senescence and apoptosis PubMed:18267069

Appears in Networks:

p(HGNC:BRAF, var(p.Val600Glu)) increases act(p(HGNC:RPS6KA6), ma(kin))

Two days after BRAFE600 selection, we seeded cells at low density and performed growth curves. RSK4 inhibition partially rescued BRAFE600-induced senescence in both TIG3 and TIG3 p16-null (Figure 4A). PubMed:21239520

Appears in Networks:

p(HGNC:BRAF, var(p.Val600Glu)) increases bp(GOBP:"oncogene-induced cell senescence")

In the present study, we found that when RSK4 is inhibited in vitro using short hairpin RNA technology, cells can bypass stress-induced senescence and oncogene-induced senescence: normal human fibroblasts grew following oxidative stress, induction of DNA damage and KRAS(V12) or BRAF(E600) overexpression. PubMed:21239520

p(HGNC:BRAF, var(p.Val600Glu)) increases bp(GOBP:"oncogene-induced cell senescence")

Following expression of BRAFV600E in melanocytes, the majority of cells became senescent (Figure 1D and data not shown), consistent with previous studies (Michaloglou et al., 2005) PubMed:18267069

p(HGNC:BRAF, var(p.Val600Glu)) increases p(MGI:Igfbp7)

Here we perform genome-wide RNA-interference screening to identify 17 genes required for an activated BRAF oncogene (BRAFV600E) to block proliferation of human primary fibroblasts and melanocytes. Surprisingly, we find a secreted protein, IGFBP7, has a central role in BRAFV600E-mediated senescence and apoptosis PubMed:18267069

Appears in Networks:

p(HGNC:BRAF, var(p.Val600Glu)) increases act(p(MGI:Rps6ka6), ma(kin))

Two days after BRAFE600 selection, we seeded cells at low density and performed growth curves. RSK4 inhibition partially rescued BRAFE600-induced senescence in both TIG3 and TIG3 p16-null (Figure 4A). PubMed:21239520

Appears in Networks:

p(HGNC:BRAF, var(p.Val600Glu)) increases p(RGD:Igfbp7)

Here we perform genome-wide RNA-interference screening to identify 17 genes required for an activated BRAF oncogene (BRAFV600E) to block proliferation of human primary fibroblasts and melanocytes. Surprisingly, we find a secreted protein, IGFBP7, has a central role in BRAFV600E-mediated senescence and apoptosis PubMed:18267069

Appears in Networks:

p(HGNC:BRAF, var(p.Val600Glu)) increases act(p(RGD:Rps6ka6), ma(kin))

Two days after BRAFE600 selection, we seeded cells at low density and performed growth curves. RSK4 inhibition partially rescued BRAFE600-induced senescence in both TIG3 and TIG3 p16-null (Figure 4A). PubMed:21239520

Appears in Networks:

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:Neoplasms)

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

p(HGNC:BRAF, var(p.Val600Glu)) negativeCorrelation path(MESHD:"Adenoma, Villous")

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:"Colorectal Neoplasms")

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

p(HGNC:BRAF, var(p.Val600Glu)) positiveCorrelation path(MESHD:"Carcinoma, Medullary")

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

p(HGNC:BRAF, var(p.Val600Glu)) association path(DO:"neuroendocrine carcinoma")

BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D). PubMed:23114745

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:"Colorectal Neoplasms")

The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high frequency in melanoma and certain subtypes of colorectal cancer. PubMed:23406774

Annotations
Experimental Factor Ontology (EFO)
SW620 cell
MeSH
Colonic Neoplasms
Evidence and Conclusion Ontology
RNAi
MeSH
Colon
NCBI Taxonomy Names
Homo sapiens

p(HGNC:BRAF, var(p.Val600Glu)) decreases bp(GOBP:"immune response")

Although pharmacologic inhibition of BRAF(V600E) in melanoma patients, which is linked to immune suppression, results in an initial response rate, these responses are typically of limited duration. PubMed:22355009

Annotations
MeSH
Peroxisomes
Experimental Factor Ontology (EFO)
COLO205
MeSH
Melanoma
Evidence and Conclusion Ontology
dominant_negative mutant
MeSH
Blood Platelets
MeSH
Endothelium, Vascular
NCBI Taxonomy Names
Homo sapiens
NCBI Taxonomy Ids
10117

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"immune response")

These findings suggest that future trials combining specific BRAF(V600E) inhibition with immunotherapy should not impair immune response. PubMed:22355009

Annotations
MeSH
Peroxisomes
Experimental Factor Ontology (EFO)
COLO205
MeSH
Melanoma
Evidence and Conclusion Ontology
dominant_negative mutant
MeSH
Blood Platelets
MeSH
Endothelium, Vascular
NCBI Taxonomy Names
Homo sapiens
NCBI Taxonomy Ids
10117

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"Wnt signaling pathway")

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
NCBI Taxonomy Ids
9606
Experimental Factor Ontology (EFO)
SW480
Disease Ontology (DO)
colorectal cancer
MeSH
Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) association p(HGNC:SHH)

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
NCBI Taxonomy Ids
9606
Experimental Factor Ontology (EFO)
SW480
Disease Ontology (DO)
colorectal cancer
MeSH
Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"phosphatidylinositol 3-kinase signaling")

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
NCBI Taxonomy Ids
9606
Experimental Factor Ontology (EFO)
SW480
Disease Ontology (DO)
colorectal cancer
MeSH
Neoplasms

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"Wnt signaling pathway")

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
MeSH
Microtubules
Experimental Factor Ontology (EFO)
SW480
MeSH
Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"phosphatidylinositol 3-kinase signaling")

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
MeSH
Microtubules
Experimental Factor Ontology (EFO)
SW480
MeSH
Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) association p(HGNC:SHH)

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
MeSH
Microtubules
Experimental Factor Ontology (EFO)
SW480
MeSH
Neoplasms
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Disease Ontology (DO)
colorectal cancer
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) positiveCorrelation path(MESHD:"Carcinoma, Medullary")

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

p(HGNC:BRAF, var(p.Val600Glu)) negativeCorrelation path(MESHD:"Adenoma, Villous")

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:"Colorectal Neoplasms")

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

p(HGNC:BRAF, var(p.Val600Glu)) association path(DO:"neuroendocrine carcinoma")

BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D). PubMed:23114745

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:Neoplasms)

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

Annotations
NCBI Taxonomy Ids
9606
Uberon
colon

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"Wnt signaling pathway")

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

p(HGNC:BRAF, var(p.Val600Glu)) association p(HGNC:SHH)

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"phosphatidylinositol 3-kinase signaling")

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

p(HGNC:BRAF, var(p.Val600Glu)) positiveCorrelation path(MESHD:"Carcinoma, Medullary")

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

Appears in Networks:
Annotations
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
NCBI Taxonomy Names
Mus musculus

p(HGNC:BRAF, var(p.Val600Glu)) negativeCorrelation path(MESHD:"Adenoma, Villous")

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

Appears in Networks:
Annotations
MeSH
Cytoplasm
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Uberon
colon

p(HGNC:BRAF, var(p.Val600Glu)) association path(DO:"neuroendocrine carcinoma")

BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D). PubMed:23114745

Appears in Networks:
Annotations
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
NCBI Taxonomy Names
Mus musculus

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:"Colorectal Neoplasms")

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

Appears in Networks:
Annotations
MeSH
Cytoplasm
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
NCBI Taxonomy Names
Mus musculus

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:Neoplasms)

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

Appears in Networks:
Annotations
MeSH
Cytoplasm
MeSH
Condylomata Acuminata
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Plasma
NCBI Taxonomy Names
Mus musculus
Uberon
colon
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:Neoplasms)

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

Annotations
Experimental Factor Ontology (EFO)
DLD-1 cell
MeSH
Cytoplasm
MeSH
Colorectal Neoplasms
MeSH
Colon
Uberon
colon
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"phosphatidylinositol 3-kinase signaling")

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
Experimental Factor Ontology (EFO)
SW480
MeSH
Intracellular Space
MeSH
Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) positiveCorrelation path(MESHD:"Carcinoma, Medullary")

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

p(HGNC:BRAF, var(p.Val600Glu)) association p(HGNC:SHH)

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
Experimental Factor Ontology (EFO)
SW480
MeSH
Intracellular Space
MeSH
Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) negativeCorrelation path(MESHD:"Adenoma, Villous")

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

Annotations
Experimental Factor Ontology (EFO)
DLD-1 cell
MeSH
Cytoplasm
MeSH
Colorectal Neoplasms
MeSH
Colon
Uberon
colon
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:"Colorectal Neoplasms")

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:"Colorectal Neoplasms")

The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high frequency in melanoma and certain subtypes of colorectal cancer. PubMed:23406774

Annotations
Experimental Factor Ontology (EFO)
SW1116 cell
MeSH
Microtubules
MeSH
Neoplasms
Evidence and Conclusion Ontology
cell viability assay
MeSH
Serum
MeSH
Plasma
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"Wnt signaling pathway")

In this study we report a molecular profile for a BRAF oncogenic mutation BRAFV600E in colon using the Illumina 45,000 gene microarray. Key differentially expressed genes have been identified from the array analysis further verified by qPCR analysis. Ingenuity pathway analysis such as microsatellite instability, kinase signalling, apoptosis, WNT and Integrin signalling is presented. MutBRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways, like PI3K. PubMed:22515520

Annotations
Experimental Factor Ontology (EFO)
SW480
MeSH
Intracellular Space
MeSH
Neoplasms
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) decreases bp(GOBP:"immune response")

Although pharmacologic inhibition of BRAF(V600E) in melanoma patients, which is linked to immune suppression, results in an initial response rate, these responses are typically of limited duration. PubMed:22355009

Annotations
Experimental Factor Ontology (EFO)
SW620 cell
Experimental Factor Ontology (EFO)
WiDr cell
Experimental Factor Ontology (EFO)
HCT116
Experimental Factor Ontology (EFO)
HCT15
MeSH
Peroxisomes
MeSH
Melanoma
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Macrophages
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"immune response")

These findings suggest that future trials combining specific BRAF(V600E) inhibition with immunotherapy should not impair immune response. PubMed:22355009

Annotations
Experimental Factor Ontology (EFO)
SW620 cell
Experimental Factor Ontology (EFO)
WiDr cell
Experimental Factor Ontology (EFO)
HCT116
Experimental Factor Ontology (EFO)
HCT15
MeSH
Peroxisomes
MeSH
Melanoma
Evidence and Conclusion Ontology
immunohistochemistry
MeSH
Macrophages
NCBI Taxonomy Names
Homo sapiens
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
10090

p(HGNC:BRAF, var(p.Val600Glu)) association path(DO:"neuroendocrine carcinoma")

BRAF/KRAS mutations were found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D) (n=2), KRAS(G12V) or KRAS(G13D). PubMed:23114745

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:Neoplasms)

KRAS mutation was noted more frequently in LST (13/36, 36.1%) than polypoid neoplasms (5/34, 14.7%, p‚Äâ=‚Äâ0.041). When comparing with LST-NG, LST-G had a significantly higher frequency of KRAS mutation. (9/16, 56.3% vs. 4/20, 20.0%, p‚Äâ=‚Äâ0.024). BRAF mutation (V600E) was found in 2 of 36 (5.6%)LSTs and 1 of 34 (2.9%) polypoid lesions. The two LST lesions with BRAF mutation were pathologically proven to be serrated adenoma. PIK3CA mutation (exon 9 E545K) was identified only in LST (5/36, 13.9%). Mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner. All mutations were absent in the specimens obtained from depressed type neoplasms. PubMed:25551625

p(HGNC:BRAF, var(p.Val600Glu)) positiveCorrelation path(MESHD:"Carcinoma, Medullary")

Lymph node metastasis of MC was significantly lower than that of poorly differentiated adenocarcinoma/undifferentiated adenocarcinoma (PDA/UDA). In addition, MC had a higher MMRd rate (0.892, 95% CI 0.758-0.956), higher BRAF(V600E) mutation rate (0.652, 95% CI 0.143-0.954) and lower KRAS mutation rate (0.171, 95% CI 0.065-0.378) than PDA/UDA and conventional adenocarcinoma. PubMed:27001432

p(HGNC:BRAF, var(p.Val600Glu)) negativeCorrelation path(MESHD:"Adenoma, Villous")

Mutations of KRAS at codon 12 or 13 were observed in 43.6% (24/55) of lesions, whereas V600E BRAF mutations were found in only 3.6% (2/55) of lesions. The frequency of BRAF mutations in this classical LST group was much lower than that in the entire cohort (18/134, 13.4%), and in this respect, it was noteworthy that 17/19 (79%) SSAs within the overall cohort contained a BRAF mutation. PubMed:23354161

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:"Colorectal Neoplasms")

The V600E mutation of BRAF was initially described in 2002 and has been found at particularly high frequency in melanoma and certain subtypes of colorectal cancer. PubMed:23406774

p(HGNC:BRAF, var(p.Val600Glu)) decreases bp(GOBP:"immune response")

Although pharmacologic inhibition of BRAF(V600E) in melanoma patients, which is linked to immune suppression, results in an initial response rate, these responses are typically of limited duration. PubMed:22355009

p(HGNC:BRAF, var(p.Val600Glu)) association bp(GOBP:"immune response")

These findings suggest that future trials combining specific BRAF(V600E) inhibition with immunotherapy should not impair immune response. PubMed:22355009

p(HGNC:BRAF, var(p.Val600Glu)) biomarkerFor bp(MeSH:Prognosis)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. PubMed:27034809

p(HGNC:BRAF, var(p.Val600Glu)) biomarkerFor bp(MeSH:Prognosis)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. PubMed:27034809

Annotations
Experimental Factor Ontology (EFO)
HT-29
MeSH
Intracellular Space
MeSH
Condylomata Acuminata
MeSH
Mucus
NCBI Taxonomy Names
Crataegus azarolus
Disease Ontology (DO)
colorectal cancer
Uberon
intestinal epithelium
Cell Ontology (CL)
stem cell
NCBI Taxonomy Ids
9606

p(HGNC:BRAF, var(p.Val600Glu)) association path(MESHD:"Colorectal Neoplasms")

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. PubMed:27034809

p(HGNC:BRAF, var(p.Val600Glu)) biomarkerFor bp(MeSH:Prognosis)

Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. PubMed:27034809

Annotations
Disease Ontology (DO)
colorectal cancer

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of the open source project, PyBEL. Please feel free to contact us here to give us feedback or report any issues.